Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III AZD0780 outcomes trial in ASCVD or high-risk primary prevention
CTR20253723Phase 3Active
- Sponsor
- AstraZeneca
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of laroprovstat in atherosclerotic disease, hypercholesterolemia, sponsored by AstraZeneca. Started Nov 2025; status: active.
02
Drugs
laroprovstat
03
Conditions
atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on CTR20253723.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253723.